|Dr. Waleed H. Hassanein M.D.||Founder, Pres, MD, CEO & Director||992.42k||7.62M||1968|
|Mr. Stephen Gordon||CFO. Treasurer & Sec.||529.32k||1.79M||1968|
|Dr. Tamer I. Khayal M.D.||Chief Commercial Officer||551.37k||1.67M||1969|
|Ms. Miriam C. Provost Ph.D.||VP of Global Regulatory Affairs||439.19k||158.85k||N/A|
|Ms. Laura Damme||VP of Clinical Affairs||337.31k||N/A||N/A|
|Mr. John F. Carey||VP of Operations||N/A||N/A||1965|
|Mr. Ike Okonkwo||VP of Fin. & Accounting||N/A||N/A||1971|
|Mr. Mark Anderson||Sr. Director of Technology Devel.||N/A||N/A||N/A|
|Ms. Susan Goodman||VP of HR||N/A||N/A||N/A|
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc.’s ISS Governance QualityScore as of June 1, 2022 is 5. The pillar scores are Audit: 5; Board: 2; Shareholder Rights: 3; Compensation: 10.